Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0009922814542481 http://scihub22266oqcxt.onion/10.1177/0009922814542481 C5958908!5958908!25027265     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pediatr+(Phila) 2015 ; 54 (1): 19-24 Nephropedia Template TP {{tp|p=25027265|t=2015. Topiramate for Weight Reduction in Adolescents with Severe Obesity |pdf=|usr=}}{{25027265}} gab.com Text Topiramate for Weight Reduction in Adolescents with Severe Obesity JO: Clin Pediatr (Phila) http://www.kidney.de/pget.php?&tw=1&pmid=25027265 #FOAvip Background: Medications for use as an adjunct to lifestyle modification (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective: To examine the effect of topiramate plus LSM on BMI reduction in adolescents with severe obesity. Methods: Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results: Twenty-eight patients (mean age 15.2±2.5 years, mean baseline BMI 46.2±10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was ?4.9, 95% CI (?7.1, ?2.8), p <0.001. Conclusions: Topiramate with concurrent LSM was associated with clinically-meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. Twit Text FOAVip Topiramate for Weight Reduction in Adolescents with Severe Obesity ????Clin Pediatr (Phila) http://www.kidney.de/pget.php?&tw=1&pmid=25027265 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25027265 #FOAvip English Wikipedia <ref>{{Cite pmid|25027265}}</ref> Topiramate for Weight Reduction in Adolescents with Severe Obesity #MMPMID25027265 Fox CK; Marlatt KL; Rudser KD; Kelly AS Clin Pediatr (Phila) 2015[Jan]; 54 (1): 19-24 PMID25027265show ga Background: Medications for use as an adjunct to lifestyle modification (LSM) for severe adolescent obesity are limited. Topiramate results in weight reduction in adults with obesity, but has not been studied in adolescents. Objective: To examine the effect of topiramate plus LSM on BMI reduction in adolescents with severe obesity. Methods: Data for this retrospective chart review were collected from patients attending a pediatric weight management program who were treated with LSM plus topiramate for 3 months minimum. Mean BMI percent change from baseline was evaluated using t-tests. Results: Twenty-eight patients (mean age 15.2±2.5 years, mean baseline BMI 46.2±10.3 kg/m2) were identified for inclusion. The 6-month percent change in BMI was ?4.9, 95% CI (?7.1, ?2.8), p <0.001. Conclusions: Topiramate with concurrent LSM was associated with clinically-meaningful BMI reduction in adolescents with severe obesity. Randomized controlled clinical trials examining efficacy and safety of topiramate for severe obesity in adolescents are needed. äTopiramate for Weight Reduction in Adolescents with Severe Obesity (epmc).pdf DeepDyve Pubget Overpricing